Charles River Laboratories International (CRL) Q3 FY2026 earnings: revenue $983 million, down 2.2% on the year

Charles River Laboratories International, Inc. (CRL) reported revenue of $983 million for Q3 FY2026, the quarter ended 26 September 2026, down 2.2% on the same quarter a year earlier. Net income was $333 million, up 512.0% on the year, and diluted earnings per share $6.86. The figures are the company's own, from the 10-Q it filed with the SEC on 4 November 2026.

Revenue

$983 million

-2.2% on the year · -2.1% on the quarter

Q4 FY2024Q3 FY2026

Operating margin

20.6%

13.3% a year earlier

Q4 FY2024Q3 FY2026

Net income

$333 million

+512.0% on the year

Q4 FY2024Q3 FY2026

Diluted EPS

$6.86

+523.6% on the year

Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 6 raised, 2 lowered, 1 new, 3 kept.

Revenue down, organic revenue up: Reported revenue was $982.7 million, down 2.2% mainly on May 2026 divestitures. Organic revenue grew 4.7%, led by Manufacturing and DSA.
Non-GAAP EPS up 27.2%: Non-GAAP diluted EPS was $3.09, up from $2.43, driven primarily by the higher operating margin and a lower tax rate.
GAAP EPS lifted by tax reversal: GAAP diluted EPS was $6.86, against $1.10 a year earlier. The benefit was $5.06 per share from reversing acquired tax reserves.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Revenue	983	1,004	1,005	-2.1%	-2.2%
Cost of revenue	625	641	666	-2.5%	-6.2%
Gross profit	358	363	339	-1.5%	+5.6%
Gross margin	36.4%	36.2%	33.7%
Selling, general and administrative	141	229	178	-38.6%	-20.8%
Operating income	203	120	134	+69.0%	+51.4%
Operating margin	20.6%	11.9%	13.3%
Interest expense	28.5	30.3	25.4	-6.0%	+12.3%
Income tax	-164	53.9	31.6
Net income	333	-1.5	54.4		+512.0%
Net margin	33.9%	-0.1%	5.4%
Diluted EPS	$6.86	-$0.03	$1.10		+523.6%

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Operating cash flow	254	180	214	+41.4%	+18.8%
Capital expenditure	46.8	31.1	35.6	+50.5%	+31.6%
Free cash flow	207	149	178	+39.5%	+16.3%
Free cash flow margin	21.1%	14.8%	17.7%
Cash from investing	10.2	28.1	-33.7	-63.6%
Cash from financing	-254	-165	-153
Depreciation and amortisation	72.3	67.3	85.2	+7.4%	-15.2%
Share-based compensation	20.8	19.8	23.3	+5.0%	-10.7%
Buybacks	0.2	116	0.1	-99.8%	+140.9%
Diluted shares, weighted	49m	48m	49m	+1.2%	-1.7%
Shares outstanding at period end	48m	48m	49m	+0.3%	-2.7%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Shareholders' equity	3,227	2,840	3,405	+13.6%	-5.2%
Non-controlling interest	5.1	6.4	4.9	-20.0%	+4.2%
Redeemable equity	43.2	42.5	40.5	+1.5%	+6.6%
Debt	2,443	2,620	2,185	-6.7%	+11.8%
Operating lease liabilities	405	408	443	-0.6%	-8.5%
Other liabilities	1,327	1,616	1,434	-17.9%	-7.5%
Total liabilities and equity	7,452	7,532	7,514	-1.1%	-0.8%
Fixed assets	1,497	1,495	1,592	+0.2%	-5.9%
Goodwill	3,084	3,077	2,922	+0.2%	+5.5%
Intangible assets	239	253	571	-5.7%	-58.2%
Cash and equivalents	200	192	207	+4.4%	-3.2%
Receivables	735	712	734	+3.3%	+0.1%
Inventory	320	346	303	-7.7%	+5.6%
Other assets	1,376	1,457	1,185	-5.6%	+16.2%
Total assets	7,452	7,532	7,514	-1.1%	-0.8%

Questions

What was Charles River Laboratories International's revenue in Q3 FY2026?

Charles River Laboratories International (CRL) reported revenue of $983 million for Q3 FY2026, the quarter ended 26 September 2026, down 2.2% on the same quarter a year earlier.

How much did Charles River Laboratories International earn in Q3 FY2026?

Net income for Q3 FY2026 was $333 million, up 512.0% on the year, and diluted earnings per share $6.86.

When did Charles River Laboratories International report Q3 FY2026 results?

Charles River Laboratories International filed its 10-Q for the quarter ended 26 September 2026 with the SEC on 4 November 2026.

Quarterly results, the last 20 quarters

	Q4 FY2021 *	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022 *	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	905	914	973	989	1,100	1,029	1,060	1,027	1,013	1,012	1,026	1,010	1,003	984	1,032	1,005	994	996	1,004	983
Cost of revenue	558	577	616	619	701	652	661	665	649	667	672	661	718	666	675	666	685	701	641	625
Gross profit	347	337	357	370	399	378	399	362	364	345	354	349	284	318	357	339	310	295	363	358
Gross margin	38%	37%	37%	37%	36%	37%	38%	35%	36%	34%	34%	35%	28%	32%	35%	34%	31%	30%	36%	36%
SG&A	144	150	132	184	200	175	200	176	197	186	170	199	196	178	192	178	196	159	229	141
Operating income	173	149	187	151	164	168	165	152	133	126	152	117	-168	74.7	100	134	-283	120	120	203
Operating margin	19%	16%	19%	15%	15%	16%	16%	15%	13%	12%	15%	12%	-17%	8%	10%	13%	-29%	12%	12%	21%
Interest expense	11.5	9.4	3.7	11.4	34.8	34.4	35.0	33.7	33.5	35.0	32.8	30.3	28.2	27.9	30.0	25.4	23.8	26.7	30.3	28.5
Net income	138	93.0	109	96.5	187	103	97.0	87.4	187	73.0	94.1	69.7	-214	25.5	52.3	54.4	-277	-14.8	-1.5	333
Net margin	15%	10%	11%	10%	17%	10%	9%	9%	18%	7%	9%	7%	-21%	3%	5%	5%	-28%	-1%	-0%	34%
Diluted EPS	$2.67	$1.81	$2.13	$1.88	$3.65	$2.01	$1.89	$1.69	$3.62	$1.30	$1.74	$1.33	-$4.22	$0.50	$1.06	$1.10	-$5.62	-$0.30	-$0.03	$6.86
Operating cash flow	229	103	149	133	235	109	148	205	221	130	194	252	159	172	205	214	148	41.1	180	254
Capital expenditure	98.8	80.5	82.9	72.4	89.0	107	67.4	65.9	78.3	79.1	39.5	38.7	75.6	59.3	35.3	35.6	89.0	55.9	31.1	46.8
Free cash flow	130	22.2	66.6	60.4	146	2.5	80.7	140	143	50.7	154	213	83.7	112	169	178	58.6	-14.8	149	207
Buybacks	0.3	34.0	4.5	0.0	0.2	19.0	5.0	0.0	0.1	9.4	8.9	101	0.1	353	7.4	0.1	0.1	208	116	0.2
Shares outstanding	50m	51m	51m	51m	51m	51m	51m	51m	51m	52m	52m	51m	51m	49m	49m	49m	49m	48m	48m	48m
Filing	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 26 September 2026, filed 4 November 2026: the filing.